Molecular Imaging in Breast Cancer Drug Development: The Next Leap Forward

As cancer treatments evolve toward personalized care, molecular imaging has become essential to optimize drug development and clinical decision-making. The functional assessment provided by new imaging techniques may address challenges in traditional approaches, help develop new precision therapies and ensure these therapies target the correct patients through biomarker selection.

FES-PET uses a Fluoroestradiol F-18 to visualize and measure the concentration of estrogen receptors in the body. It is a relatively new imaging technique with potential clinical applications in breast cancer.

Join Gisela Menezes Montgomery, MD, PhD as she:

Compares the use of FDG-PET and FES-PET to guide personalized therapy in breast cancer patients
Discusses the impact of FES-PET imaging in breast cancer treatment decision-making
Examines other recent advances in molecular breast cancer imaging

GISELA MONTGOMERY, M.D., PH.D.

Medical Director, Invicro

Dr. Montgomery holds two medical degrees, one from the Superior School of Health Sciences, Brazil and another from the University of Porto, Portugal. She completed her residency in Radiology and earned a Ph.D. from the University of Utrecht (Netherlands) in breast cancer imaging.

Dr. Montgomery has seven years of national and international experience in breast cancer imaging clinical trials phases I-IV, and published several scientific peer-reviewed manuscripts in journals, such as Radiology and European Radiology, as first author. She has expertise in protocol design, statistical analysis, imaging evaluation, regulatory affairs, artificial intelligence and business development.

WEBINAR SERIES

Molecular Imaging in Breast Cancer Drug Development: The Next Leap Forward

About The Speaker